Trial Profile

A Phase 2b trial assessing IRL 201104 in patients with active eosinophilic esophagitis (EoE)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 19 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IRL 201104 (Primary)
Indications Eosinophilic oesophagitis
Focus Therapeutic Use

Most Recent Events

12 Dec 2024 According to Revolo Biotherapeutics media release, the company top priority is to initiate a clinical study with SQ formulation in eosinophilic esophagitis early in 2025
26 Sep 2023 New trial record
21 Sep 2023 According to Revolo Biotherapeutics media release, the company is working diligently to initiate this trial in H1 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com